Publications

Predictive biomarkers of systemic treatment in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.

CA McIntyre, E Dekker, M Gonen, MG Besselink, MYV Homs, B Mostert, ...

Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: a post hoc analysis of the CALGB (Alliance)/SWOG 80702 phase 3 randomized clinical trial

GQ Zhang, JA Meyerhardt, Q Shi, T Twombly, L Pederson, C Ma, ...

Prognostic value of CT radiomics in patients with gBRCA1/2 and PALB2 and advanced pancreas cancer.

S Gandhi, J Chakraborty, H Ghahremannezhad, R Do, N Horvat, KH Yu, ...

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, et al.

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer

MN Karam, J Hajj, CH Crane, P Ramia, F Geara, N Hamadeh, JG Scott, ...

Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2 …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, D Sohal, S Colby, ...

Response to Letter to the Editor:‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of …

T Macarulla, RP Cid, MS Womack, AC Gracian, A Zervoudakis, H Hatoum, ...

Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium

EN Dekker, D van Klaveren, EMM Verkolf, RF de Wilde, MG Besselink, ...

Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).

I Garrido-Laguna, W Park, DS Hong, M Pelster, B Herzberg, AI Spira, ...

Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model

H Yarmohammadi, SY Son, AWP Maxwell, AS Elsakka, VS Sotirchos, ...

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al.

Su1848 ENDOSCOPIC ULTRASOUND-GUIDED BIOMARKER EVALUATION OF PANCREATIC CANCER AFTER EXPOSURE TO THERAPY

SE Lee, D Kim, VS Rolston, E Vakiani, C Sigel, EM O’Reilly, K Yu, ...

Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer

A Dhyani, N Tezcan, JF Chou, Z Tarcan, R Thummalapalli, F Nagib, ...

Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation

Cardell CF, Segovia D, Prakash LR, Zemla T, Shi Q, Ahmad S, Herman JM, O'Reilly EM, et al.

The Development of Second-Generation KRAS Inhibitors

EM O’Reilly

The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

CS Leonhardt, M Adham, S Bazarbashi, I Ben-Aharon, RGH Beets-Tan, ...

Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling.

OM Fitzpatrick, D Cowzer, R Thummalapalli, J Chou, F Nagib, M Dunphy, ...

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer

Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, et al.

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

May MS, Park W, O'Reilly EM

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here: MS May et al.

MS May, W Park, EM O’Reilly

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma

Paudyal R, Russell J, Lekaye HC, Deasy JO, Humm JL, Awais M, Nadeem S, Do RKG, et al.

Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study

Oh M, Chang L, Matney C, Fuldeore R, Perez E, Alici Y, Buzaglo J, Mao M, et al.

Universal Germline Genetic Testing after a Diagnosis of Cancer

ZK Stadler, A Maio, A Khurram, K Arora, C Bandlamudi, YL Liu, Y Kemel, ...

111O The mechanism of mismatch repair deficiency (MMRd) informs survival outcomes derived from immune checkpoint blockade (ICB) across MMRd solid tumors

V Randrian, K Sweeney, E Alouani, P Johannet, O Artz, MB Foote, ...

1712P Efficacy and safety of cabozantinib (CABO) for advanced lung and thymic neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of phase III …

EM Wolin, T Zemla, S Geyer, JR Strosberg, TR Halfdanarson, N Trikalinos, ...

2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+, advanced solid tumors: phase I/Ib trial

K Shitara, HJ Choi, F Dayyani, S Kazmi, I Korakis, RH Moy, EM O'reilly, ...

2223P First-line (1L) AZD0171+ durvalumab (D)+ chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results

S Chandana, A Ruiz-Casado, RA Gallego, AL Coveler, R El-Maraghi, ...

2228P the SHARON trial: melphalan, BCNU, hydroxocobalamin, ascorbic acid, and stem cells for pancreatic and breast cancer and an inherited BRCA/PALB2 mutation

KH Yu, P Dahi, CD Weekes, YB Chen, J Glazier, A Glazier, S Giralt, ...

261MO A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations

D Ahn, A Ulrich, W Park, S McCue, FS Ou, N Tran, LAK Fonkoua, ...

350P IDH2-mutated cholangiocarcinoma: a case series highlighting challenges and insights

L Al Mahmasani, JJ Harding, R Thummalapalli, D Khalil, A Yaqubie, ...

384TiP quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial

TM Mercade, T Bekaii-Saab, K Feeney, EM O'Reilly, S Pant, JO Park, ...

707 Mechanism of MLH1 inactivation predicts benefit to dual immune checkpoint blockade in mismatch repair deficient tumors

B Rousseau, V Randrian, K Sweeney, M Khushman, E Alouani, ...

752P Clinical outcome of patients (pts) with sporadic vs Lynch syndrome-related stage III colon carcinoma (CC) with deficient mismatch repair (dMMR) treated in a randomized …

FA Sinicrope, FS Ou, A Reinacher-Schick, RJ Behrens, WR Peters, ...

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

ZA Wainberg, D Melisi, T Macarulla, R Pazo Cid, SR Chandana, ...

Abstract A088: Genomic Scar to Immune Signals: Translational Insights from the POLAR Trial Reveal POLQ-Driven Immunogenicity in HRD Pancreatic Cancer

W Park, C O'Connor, M Hilmi, S Umeda, R Sharma, K Soares, ...

Abstract A097: Impact of socioeconomic status on survival outcomes in patients with stage IV pancreatic adenocarcinoma: A race/ethnicity controlled analysis

A Erakky, S Nandakumar, M Waters, J Duque-Jimenez, A Awuah, M Lao, ...

Abstract A113: Cachexia and Depression in Pancreatic Cancer (PC) Associate with Myeloid Inflammation and Tumor-Intrinsic Metabolic Stress

J Song, M Hilmi, C O'Connor, H Martirosova, J Schoenfeld, A Hilmi, ...

Abstract A125: Tumor cell plasticity, stromal rewiring, and clonal T cell expansion define response and resistance to combined PARP and PD-1 blockade (POLAR) in pancreatic cancer

M Hilmi, J Park, W Mckerrow, S Umeda, C O'Connor, Y Elhanati, ...

Abstract B044: Black and Hispanic patients with pancreatic ductal adenocarcinoma (PDAC) have worse overall survival than Asian and White patients with PDAC, despite having more …

JB Duque-Jimenez, AN Awuah, A Erakky, S Nandakumar, M Waters, ...

Abstract B047: DNA Damage Repair (DDR) Variants Beyond BRCA/PALB2 in Pancreatic Adenocarcinoma (PDAC): Evaluation of Significance

CA O'Connor, JW Lee, E Harrold, AL Richards, D Muldoon, ...

Abstract CT192: Orally administered MOMA-313 as monotherapy or combination therapy in participants with advanced or metastatic solid homologous recombination (HR)-deficient …

A Patnaik, W Abida, KA Reiss, J De Bono, R McKay, AH Bryce, ...

Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma

J Sharib, KE Rhodin, A Liu, S McIntyre, A Bartholomew, S Masoud, ...

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Tsang ES, Shi Q, Olive K, Collisson E, Dixon JG, Cusnir M, Winograd R, Botta GP, et al.

Anticoagulants or antiplatelets for secondary prevention of cryptogenic stroke: an updated systematic review and meta-analysis

Chi KY, El Zarif T, Varrias D, Lee PL, Chang YC, Song J, Osabutey A, Borkowski P, et al.

ASO Visual Abstract: Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial

EN Dekker, QP Janssen, JL van Dam, GJ Strijk, EMM Verkolf, S Kandala, ...

ASO Visual Abstract: Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

AB Blair, SN Radomski, J Chou, M Liu, TC Howell, W Park, EM O’Reilly, ...

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).

SK Char, Q Shi, T Zemla, C Ma, E Cheng, P Kumthekar, KA Guthrie, ...

Association of inflammation with depression in pancreatic ductal adenocarcinoma.

J Song, DH Hong, S Park, M Hilmi, JD Schoenfeld, A Hilmi, H Martirosova, ...

Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study …

KH Lim, RA Safyan, K Perez, KR Spencer, EM O'Reilly, AH Ko, A Shergill, ...